Linked Life Data

15140544

Source:http://linkedlifedata.com/resource/pubmed/id/15140544

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2004-5-13
pubmed:abstractText
ERCC1 (excision repair cross-complementation group 1) and XPD (ERCC2, excision repair cross-complementation group 2) as genes have been known to be belonged to the nucleotide excision repair pathway and therefore related to DNA repair. Polymorphisms in these genes have been rarely evaluated in terms of predicting cancer patient survival. We investigated whether these polymorphisms have an effect on response to chemotherapy and survival in 109 patients with non-small-cell lung cancer treated with cisplatin combination chemotherapy. Polymorphisms of ERCC1 Asn118Asn (C --> T), XPD Lys751Gln (A --> C) and Asp312Asn (G --> A) were evaluated using a SNaPshot kit. As for chemotherapy response, treatment response did not show statistically significant differences between the wild genotypes and the variant genotypes for the ERCC1 and XPD gene. The median survival time of all patients was 376 days (95% CI, 291-488). As for survival rate according to the polymorphism of codon 118 in ERCC1, median survival time in patients showing C/C genotype was 486 days (95% CI, 333-x), which was significantly different from the 281 days (95% CI, 214-376) of patients with the variant genotype (T/T or C/T) (P = 0.0058). Using the Cox-proportional hazards model, the polymorphism of codon 118 in ERCC1, response to chemotherapy, weight loss and performance status effected overall survival significantly (P = 0.0001, 0.0001, 0.0028 and 0.0184, respectively). However, polymorphisms of codons 751 and 312 in the XPD gene did not affect patient survival (P = 0.4711 and 0.4542, respectively). Therefore, we suggest that the C/C genotype in codon 118 of ERCC1 is a surrogate marker for predicting better survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0169-5002
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
311-6
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:15140544-Adult, pubmed-meshheading:15140544-Aged, pubmed-meshheading:15140544-Antineoplastic Agents, pubmed-meshheading:15140544-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:15140544-Cisplatin, pubmed-meshheading:15140544-DNA Helicases, pubmed-meshheading:15140544-DNA-Binding Proteins, pubmed-meshheading:15140544-Endonucleases, pubmed-meshheading:15140544-Female, pubmed-meshheading:15140544-Humans, pubmed-meshheading:15140544-Lung Neoplasms, pubmed-meshheading:15140544-Male, pubmed-meshheading:15140544-Middle Aged, pubmed-meshheading:15140544-Polymorphism, Genetic, pubmed-meshheading:15140544-Predictive Value of Tests, pubmed-meshheading:15140544-Survival Analysis, pubmed-meshheading:15140544-Transcription Factors, pubmed-meshheading:15140544-Xeroderma Pigmentosum Group D Protein
pubmed:year
2004
pubmed:articleTitle
Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
pubmed:affiliation
Department of Internal Medicine, College of Medicine, Inha University, Incheon, Korea. jsryu@inha.ac.kr
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't